Thank you!

Your quote has been successfully submitted!

For products requiring additional information, our team will contact you within 1 business day

Failed

There was an error submitting your quote. Please try again.

Recombinant Human IL18BP Protein (Fc Tag)– MSE Supplies LLC

Free Shipping on MSE PRO Online Orders of $500 or More! U.S. Orders Only * Offer Excludes Hazmat Shipments *

Menu

This product has been added to the cart.

Recombinant Human IL18BP Protein (Fc Tag)

SKU: PKSH032626-50

  • $ 11695



Recombinant Human IL18BP Protein (Fc Tag)

 

SKU # PKSH032626
Expression Host HEK293 Cells

 

 

Description

Synonyms I18BP, IL18 BP, IL18 BPa, IL-18BP, IL18BPa, Interleukin 18 binding protein, Interleukin-18-binding protein, MC51L 53L 54L homolog gene product, Tadekinig alfa, Tadekinig-alfa, Tadekinig-alfa and IL18BP, IL18BP
Species Human
Expression Host HEK293 Cells
Sequence Thr31-Gly194
Accession O95998
Calculated Molecular Weight 44.8 kDa
Observed Molecular Weight 60-75 kDa
Tag C-Fc
Bio-activity Not validated for activity
  

 

Properties

Purity > 95 % as determined by reducing SDS-PAGE.
Endotoxin < 1.0 EU per μg of the protein as determined by the LAL method.
Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping This product is provided as lyophilized powder which is shipped with ice packs.
Formulation Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Reconstitution Please refer to the printed manual for detailed information.



Background

Interleukin-18-binding protein, also known as Tadekinig-alfa and IL18BP, contains 1 Ig-like C2-type domain. IL18BP is constitutively expressed and secreted in mononuclear cells. IL18BP functions as an IL18 inhibitor. IL18BP binds to IL18, prevents the binding of IL18 to its receptor, and thus inhibits IL18-induced IFN-gamma production. It has been shown that IL18BP may be a promising molecular approach to inhibit neointimal hyperplasia and arteriosclerosis progression following coronary and peripheral angioplasty.